{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:24:55Z","timestamp":1789575895270,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007579","name":"Auburn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.critrevonc.2021.103375","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:58:01Z","timestamp":1622591881000},"page":"103375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-1988","authenticated-orcid":false,"given":"Kaniz Afroz","family":"Tanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-5444","authenticated-orcid":false,"given":"Cong Bang","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-015-3466-4","article-title":"Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9","volume":"152","author":"Abraham","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0010","article-title":"E7389 versus capecitabine in patients with locally advanced or metastatic breast Cancer Previously treated with anthracyclines and taxanes","author":"Anon","year":"2006","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0015","author":"Anon","year":"2006"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0020","article-title":"A study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast Cancer","author":"Anon","year":"2009","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0025","series-title":"Halaven (erbulin mesylate) Injection: Highlights of Prescribing Information. US Food and Drug Administration","author":"Anon","year":"2010"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0030","article-title":"Comparison of neoadjuvant chemotherapy with weekly paclitaxel or eribulin followed by A\/C in women with locally advanced HER2-Negative breast Cancer","author":"Anon","year":"2012","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0035","article-title":"Eribulin plus gemcitabine (EG) vs paclitaxel plus gemcitabine (PG) in HER2-Negative metastatic breast Cancer","author":"Anon","year":"2014","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0040","article-title":"Eribulin versus vinorelbine in subjects with locally recurrent or metastatic breast Cancer Previously treated with anthracyclines and taxanes","author":"Anon","year":"2014","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0045","series-title":"Breast Cancer: Facts & Figures 2019-2020. American Cancer Society","author":"Anon","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0050","series-title":"Recommendations on Testing for Funnel Plot Asymmetry. Cochrane Handbook for Systematic Reviews of Interventions (Version 6.1, 2020)","author":"Anon","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0055","unstructured":"Anon Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02037529. Accessed 26 December 2020."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0060","series-title":"Research and Guidelines: Breast Cancer. American Society of Clinical Oncology (ASCO)","author":"ASCO","year":"2020"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103375_bib0065","article-title":"Why the cochrane risk of Bias tool should include funding source as a standard item","author":"Bero","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103375_bib0070","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103375_bib0075","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast Cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0080","first-page":"Cd003372","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","author":"Carrick","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103375_bib0085","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1080\/03007995.2020.1835853","article-title":"Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer","volume":"36","author":"Chabot","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103375_bib0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ctrv.2008.01.007","article-title":"Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer","volume":"34","author":"Coley","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2021.103375_bib0095","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/jco.2011.29.15_suppl.1035","article-title":"Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data","volume":"29","author":"Cortazar","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103375_bib0100","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2011.39.2613","article-title":"US Food and Drug Administration approval overview in metastatic breast cancer","volume":"30","author":"Cortazar","year":"2012","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"9769","key":"10.1016\/j.critrevonc.2021.103375_bib0105","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0110","unstructured":"CTCAE Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 30 November 2020."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00223-010-9379-7","article-title":"NSAID exposure and risk of nonunion: a meta-analysis of case\u2013control and cohort studies","volume":"87","author":"Dodwell","year":"2010","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155214525369","article-title":"A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting","volume":"21","author":"Dranitsaris","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0125","series-title":"Clinical Practice Guidelines: Breast Cancer. European Society for Medical Oncology (ESMO)","author":"ESMO","year":"2020"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103375_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures. Journal of experimental stroke & translational medicine","volume":"3","author":"Evans","year":"2010","journal-title":"J. Exp. Stroke Transl. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0135","doi-asserted-by":"crossref","first-page":"e1001026","DOI":"10.1371\/journal.pmed.1001026","article-title":"Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview","volume":"8","author":"Golder","year":"2011","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcin.2008.01.008","article-title":"Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations","volume":"1","author":"Hannan","year":"2008","journal-title":"JACC Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ebmh.10.3.67","article-title":"Appraising the evidence: what is selection bias?","volume":"10","author":"Henderson","year":"2007","journal-title":"Evidence Based Mental Health."},{"issue":"7414","key":"10.1016\/j.critrevonc.2021.103375_bib0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0160","series-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 6.1, 2020)","author":"Higgins","year":"2020"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0165","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103375_bib0170","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103375_bib0175","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.286.7.821","article-title":"Comparison of evidence of treatment effects in randomized and nonrandomized studies","volume":"286","author":"Ioannidis","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103375_bib0180","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/ijc.32402","article-title":"Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program","volume":"145","author":"Jacot","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0185","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Analysing data and undertaking meta-analyses","author":"Jonathan","year":"2021"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103375_bib0190","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0195","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-020-05867-0","article-title":"Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine","volume":"184","author":"Kazmi","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0200","article-title":"A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens","volume":"14","author":"Kikuchi","year":"2018","journal-title":"Asia. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2016.03.003","article-title":"Emerging therapeutic targets in metastatic progression: a focus on breast cancer","volume":"161","author":"Li","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0220","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.breast.2016.12.017","article-title":"Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"32","author":"Maeda","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0230","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0235","series-title":"Clinical Practice Guidelines in Oncology: Breast Cancer (version 5.2020). National Comprehensive Cancer Network","author":"NCCN","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0240","series-title":"Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. National Comprehensive Cancer Network (NCCN)","author":"NCCN","year":"2020"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103375_bib0245","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14740338.2012.698608","article-title":"Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer","volume":"11","author":"O\u2019Sullivan Coyne","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2021.103375_bib0250","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e12031","article-title":"Safety of eribulin in Korean patients with metastatic breast cancer","volume":"33","author":"Park","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0255","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2017.10.002","article-title":"Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","volume":"86","author":"Park","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103375_bib0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085035","article-title":"Using multiple types of studies in systematic reviews of health care interventions--a systematic review","volume":"8","author":"Peinemann","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0265","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14740338.2019.1608946","article-title":"The safety of eribulin for the treatment of metastatic breast cancer","volume":"18","author":"Perez-Garcia","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0270","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14740338.2019.1608946","article-title":"The safety of eribulin for the treatment of metastatic breast cancer","volume":"18","author":"Perez-Garcia","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103375_bib0275","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication Bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103375_bib0280","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/0284186X.2019.1670356","article-title":"The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry","volume":"59","author":"Pouwels","year":"2020","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0285","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0290","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctrv.2018.05.008","article-title":"Does pelvic radiation increase rectal cancer incidence? \u2013 A systematic review and meta-analysis","volume":"68","author":"Rombouts","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103375_bib0295","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12885-019-5674-5","article-title":"Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer","volume":"19","author":"Schwartzberg","year":"2019","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103375_bib0300","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.7150\/jca.37670","article-title":"Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer","volume":"11","author":"Shingaki","year":"2020","journal-title":"J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103375_bib0305","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000076","article-title":"Why the cochrane risk of Bias tool should not include funding source as a standard item","author":"Sterne","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103375_bib0310","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0315","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0320","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/1759-7714.12482","article-title":"Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice","volume":"8","author":"Tanaka","year":"2017","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0325","article-title":"Comparative effectiveness and safety of eribulin based versus non-eribulin based regimens in advanced or metastatic breast cancer: a systematic review and meta-analysis","author":"Tanni","year":"2020","journal-title":"PROSPERO: Int. Prospective Register of Sys. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103375_bib0330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"4 Supplement","key":"10.1016\/j.critrevonc.2021.103375_bib0335","article-title":"Abstract P5-15-02: phase 1b\/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer","volume":"77","author":"Tolaney","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0340","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0345","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for <em>In vivo<\/em> efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103375_bib0350","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/annonc\/mdv619","article-title":"Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis","volume":"27","author":"Truong","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103375_bib0355","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0360","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10549-013-2574-2","article-title":"Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy","volume":"140","author":"Vahdat","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103375_bib0365","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res. Synth. Methods"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103375_bib0370","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/CAD.0000000000000493","article-title":"A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer","volume":"28","author":"Voutsadakis","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0375","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s40064-015-1422-8","article-title":"Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review","volume":"4","author":"Watanabe","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0380","author":"Wells"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0385","unstructured":"WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. World Health Organization. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/69797\/WHO-EIP-SPO-QPS-05.3-eng.pdf. Accessed 30 November 2020."},{"key":"10.1016\/j.critrevonc.2021.103375_bib0390","doi-asserted-by":"crossref","first-page":"d8141","DOI":"10.1136\/bmj.d8141","article-title":"Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications","volume":"344","author":"Wieseler","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103375_bib0395","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1094428106296638","article-title":"Methodology for dealing with duplicate study effects in a meta-analysis","volume":"11","author":"Wood","year":"2007","journal-title":"Organ. Res. Methods"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103375_bib0400","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s13063-020-04341-y","volume":"21","author":"Yamashita","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0405","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103375_bib0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2018.06.003","article-title":"Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy","volume":"128","author":"Zhao","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:40:19Z","timestamp":1760902819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":82,"alternative-id":["S1040842821001633"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103375","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103375"}}